Teva Pharmaceutical Industries Limited (TEVA)’s share was trading at $16.89 as of May 14th. TEVA’s forward P/E is 6.47 according to Yahoo Finance. Teva Pharmaceuticals, the world’s largest ...

There are 873 funds or institutions reporting positions in Teva Pharmaceutical Industries Limited - Depositary Receipt (). This is an increase of 35 owner(s) or 4.18% in the last quarter. Average ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other ...

NEW YORK - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) saw its shares climb 3.7% after the company reported first quarter earnings that beat analyst expectations and raised its full-year guidance.

Teva reported Q1 adjusted earnings per share (EPS) of $0.52, solidly beating Wall Street's target of $0.48. The company missed on sales, however, reporting $3.89 billion for the quarter when $4 ...

NYSE:TEVA opened at $16.18 on Wednesday. The company has a 50-day moving average of $17.79 and a 200-day moving average of $18.21. The firm has a market cap of $18.34 billion, a price-to-earnings ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE ...

Shares of Teva Pharma marginally down 1% in early morning trading, while Alvotech's saw a 5% increase. Alvotech is in charge of development and manufacturing of Selarsdi, while Teva holds the ...

Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Teva Pharmaceutical reports fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion. Teva reports fourth-quarter adjusted earnings of 71 cents per share, beating ...

It is changing from a generics market leader into one that is starting to compete directly with Big Pharma. Overall, Teva's price/sales ratio [FWD] is 1.53x. This is not only 58.4% lower relative ...